Man Group plc Takes $1.18 Million Position in LifeStance Health Group, Inc. $LFST

Key Points

• Man Group acquired 110,155 LifeStance Health Group shares worth approximately $1.18 million, while institutional investors collectively own 85.5% of the company.
• LifeStance reported quarterly revenue of $435.35 million, up 26.1% year over year, and earnings of $0.06 per share—double analysts’ $0.03 estimate.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $12.38, although insiders sold roughly $155 million in shares during the quarter.

Man Group plc acquired a new position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 110,155 shares of the company's stock, valued at approximately $1,180,000.

Several other large investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new position in LifeStance Health Group in the second quarter valued at $389,293,000. Silversmith Partners I GP LLC acquired a new position in shares of LifeStance Health Group during the 4th quarter worth about $100,842,000. Vanguard Group Inc. boosted its stake in shares of LifeStance Health Group by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company's stock worth $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company's stock valued at $65,157,000 after acquiring an additional 2,843,388 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company's stock valued at $26,363,000 after acquiring an additional 1,839,465 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company's stock.

LifeStance Health Group Stock Up 2.3%

Shares of LFST stock opened at $12.89 on Thursday. LifeStance Health Group, Inc. has a 52-week low of $4.77 and a 52-week high of $13.15. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of 99.16 and a beta of 1.22. The firm's 50-day moving average is $11.38 and its 200-day moving average is $8.73. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analysts' expectations of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.LifeStance Health Group's quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.01) earnings per share. Sell-side analysts predict that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Analysts Set New Price Targets

LFST has been the topic of several analyst reports. Barclays upped their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, July 14th. Zacks Research lowered LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. BTIG Research upped their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, August 19th. JPMorgan Chase & Co. increased their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 14th. Finally, KeyCorp raised their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $12.38.

Insiders Place Their Bets

In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the sale, the insider owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. This represents a 12.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Bessler sold 894,337 shares of the firm's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director directly owned 539,763 shares of the company's stock, valued at $5,467,799.19. This represents a 62.36% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 14,629,850 shares of company stock valued at $154,952,012. 3.50% of the stock is owned by insiders.

LifeStance Health Group Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.